MA46988A1 - Liquid formulation of anti-tnf alpha antibodies - Google Patents

Liquid formulation of anti-tnf alpha antibodies

Info

Publication number
MA46988A1
MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
Authority
MA
Morocco
Prior art keywords
liquid formulation
tnf alpha
alpha antibodies
antibodies
tnf
Prior art date
Application number
MA46988A
Other languages
French (fr)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA46988A1 publication Critical patent/MA46988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.The present invention relates to a liquid formulation of an anti-tnf alpha antibody, in particular adalimumab.

MA46988A 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies MA46988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
MA46988A1 true MA46988A1 (en) 2020-06-30

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46988A MA46988A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies

Country Status (15)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
BR (1) BR112019019162A2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015034A2 (en) * 2019-02-18 2021-10-05 Eli Lilly And Company THERAPEUTIC ANTIBODY FORMULATION
TW202102260A (en) * 2019-03-21 2021-01-16 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815689C (en) * 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
KR20160105535A (en) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 Pharmaceutical Formulations of TNF-Alpha Antibodies
BR112015004984A2 (en) 2012-09-07 2017-07-04 Coherus Biosciences Inc stable aqueous formulations of adalimumab
CN105051064A (en) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 Tnf-alpha antigen-binding proteins
CN105025925A (en) 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 Anti-prolactin receptor antibody formulations
WO2015134406A1 (en) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
LT2946765T (en) * 2014-05-23 2016-11-25 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
AU2018236651A1 (en) 2019-10-31
MY197202A (en) 2023-05-31
AU2018236651B2 (en) 2020-12-10
ZA201906696B (en) 2020-08-26
BR112019019162A2 (en) 2020-04-14
KR20180106974A (en) 2018-10-01
RU2019130728A3 (en) 2021-04-16
JP2022097600A (en) 2022-06-30
MX2019010895A (en) 2019-11-05
CO2019010860A2 (en) 2020-01-17
KR20200096472A (en) 2020-08-12
UA123847C2 (en) 2021-06-09
RU2756619C2 (en) 2021-10-04
WO2018169348A1 (en) 2018-09-20
CN110621303A (en) 2019-12-27
PH12019502075A1 (en) 2020-09-14
NZ757965A (en) 2022-07-01
KR102342292B1 (en) 2021-12-24
JP7109849B2 (en) 2022-08-01
JP2020510079A (en) 2020-04-02
RU2019130728A (en) 2021-04-16

Similar Documents

Publication Publication Date Title
MA53356B1 (en) Subcutaneous anti-cd38 antibody formulations and uses thereof
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CL2018003520A1 (en) Anti-b7-h3 antibodies and antibody and drug conjugates.
CL2022000027A1 (en) PCSK9 antagonist compounds. (Application divisional 202003257).
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
MX2018012648A (en) Antibody-containing preparation.
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
MA40576B1 (en) Anti-her2 antibodies and immunoconjugates
MA44594B1 (en) Anti-ctla-4 Antibodies and Methods of Use thereof
MA45450B1 (en) Anti-cd19 antibody formulations
MA38632A1 (en) Anti-transferrin receptor antibody and methods of use
EA201991701A1 (en) COMPOSITION BASED ON MONOCLONAL ANTIBODY TO RSV
IN2012DN05237A (en)
MA35009B1 (en) ANTI-SCLERROTIN ANTIBODY CRYSTALS AND FORMULATIONS THEREOF
MA38828A1 (en) Antibodies to plasminogen activator inhibitor type 1 (pai-1) and their uses
CO6270369A2 (en) NEW SPECIFIC ANTIBODIES OF BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC OR DRUG AGENTS
MA37946A1 (en) Treatment of rheumatoid arthritis
MA44645B1 (en) Combined treatment of an anti-cd20 antibody with a bcl-2 inhibitor and an mdm2 inhibitor
MX2022001146A (en) Anti-pvrig antibodies formulations and uses thereof.
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies
MA38413A1 (en) Pan-elr + cxc chemokine antibody
EA201992027A1 (en) WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1
EA202092508A1 (en) COMPOSITIONS BASED ON ANTIBODIES TO HUMAN PD-L1
PH12014501985B1 (en) Il-17 antibody formulation
MA45831B1 (en) ANTI-BEDBUG MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF